Skip to main content
Apeloa Pharmaceutical Co.,Ltd. logo

Apeloa Pharmaceutical Co.,Ltd. — Investor Relations & Filings

Ticker · 000739 ISIN · CNE000000Q45 Shenzhen Stock Exchange Manufacturing
Open in API
Filings indexed 1,843 across all filing types
Latest filing 2016-06-20 Capital/Financing Update
Country CN China
Listing Shenzhen Stock Exchange 000739

About Apeloa Pharmaceutical Co.,Ltd.

https://www.apeloa.com

Apeloa Pharmaceutical Co., Ltd. focuses on the research, development, manufacturing, and distribution of active pharmaceutical ingredients (APIs), intermediates, and finished dosage forms. The company operates three core business pillars: API production, Contract Development and Manufacturing Organization (CDMO) services, and finished drug products. Its therapeutic focus includes cardiovascular, anti-infective, anti-viral, and oncology treatments. Apeloa utilizes an integrated supply chain to deliver chemical and biological solutions to a global client base. The organization maintains compliance with international quality standards, including certifications from the FDA, EMA, and PMDA. Its CDMO services encompass the full product lifecycle, from process chemistry and analytical development to large-scale commercial manufacturing, supported by specialized technology platforms such as continuous flow chemistry and enzymatic synthesis.

Recent filings

Filing Released Lang Actions
关于与中国农发重点建设基金投资有限公司合作的公告
Capital/Financing Update Classification · 95% confidence The document is an announcement by a company about a cooperation agreement involving an equity investment by a fund into its subsidiary. It details the investment amount, project description, fund management, and impact on the company. There is no financial report, audit, or earnings data presented. The document is relatively short (1314 characters) and focuses on a capital investment transaction. It is not a full financial report, earnings release, or regulatory certification. The content fits best under Capital/Financing Update (CAP) as it provides an update on a financing activity involving equity investment and capital structure changes.
2016-06-20 Chinese
2015年年度权益分派实施公告
Notice of Dividend Amount Classification · 95% confidence The document is an announcement regarding the implementation of the 2015 annual equity distribution (dividend payment) plan approved at the 2016 shareholders' meeting. It details the dividend amount per share, the record date, the ex-dividend date, the dividend recipients, and the method of dividend distribution. It references the shareholders' meeting resolution and related documents but does not contain financial statements or detailed financial performance data. The document length is short (1692 characters) and primarily serves to inform shareholders about the dividend payment details. Therefore, it fits the category of a Notice of Dividend Amount rather than an Annual Report or other financial report.
2016-06-14 Chinese
2016年第二次临时股东大会决议公告
Declaration of Voting Results & Voting Rights Announcements Classification · 95% confidence The document is a detailed announcement of the resolutions passed at an extraordinary shareholders' meeting (临时股东大会) held by 普洛药业股份有限公司 in 2016. It includes voting results for multiple proposals, attendance details, meeting procedures, and legal opinions confirming the validity of the meeting and resolutions. The content focuses on the official results of shareholder votes on specific agenda items, including non-public share issuance and related authorizations. There is no presentation material, financial statements, or management discussion, but rather a formal record of voting outcomes and meeting procedures. This matches the definition of 'Declaration of Voting Results & Voting Rights Announcements (DVA)', which covers official results from shareholder votes at any general meeting (AGM or EGM). The document length is under 5,000 characters, but it contains substantive voting results and legal opinions, not just a brief announcement or a link to a report, so it is not a Report Publication Announcement (RPA). Therefore, the correct classification is DVA with high confidence.
2016-05-09 Chinese
2016年度第二次临时股东大会的法律意见书
AGM Information Classification · 95% confidence The document is a legal opinion letter from a law firm regarding the convening and procedures of a company's 2016 second extraordinary general meeting (临时股东大会). It details the legality of the meeting's notice, attendance, voting procedures, and resolutions. It does not contain financial statements or results but focuses on the legal validation of the shareholders' meeting process and resolutions. This type of document is typically associated with the formal legal opinion provided for shareholder meetings, which is part of the materials shared during such meetings. Therefore, it fits best under the category of AGM Information (AGM-R). The document length is under 5,000 characters, but it is not merely an announcement of a report; it is the legal opinion document itself, which is part of AGM materials.
2016-05-09 Chinese
2016年第一季度报告全文
Interim / Quarterly Report Classification · 100% confidence The document is titled as the "2016 First Quarter Report" of 普洛药业股份有限公司, indicating it is a quarterly financial report. It contains detailed financial statements including consolidated balance sheets, profit and loss statements, cash flow statements, and notes on financial data for the quarter ending March 31, 2016. The presence of comprehensive financial data and analysis for a period shorter than a full fiscal year confirms it is an Interim / Quarterly Report. The document length is substantial (15,000 characters), and it contains actual financial data, not just an announcement or certification. Therefore, the appropriate classification is Interim / Quarterly Report (IR). Q1 2016
2016-04-29 Chinese
关于召开2016年第二次临时股东大会的提示性公告
Proxy Solicitation & Information Statement Classification · 100% confidence The document is a detailed announcement about the convening of the 2016 second extraordinary general meeting of shareholders for 普洛药业股份有限公司. It includes information about the meeting date, voting procedures (both in-person and online), agenda items to be discussed, registration details, and an attached proxy authorization form. There are no financial statements or financial performance data included. The document serves to inform shareholders about the meeting logistics and voting process rather than presenting financial results or management discussion. This fits the definition of a Proxy Solicitation & Information Statement (PSI), which provides materials sent to shareholders to inform and request votes for meetings.
2016-04-29 Chinese

Browse filings by year

27 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.